SXTC
NASDAQChina SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc. (SXTC) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for SXTC, including 1 offering, 1 SEC filing and 1 press release or news item. The most recent was published Oct 22, 2026.
SXTC rankings
Financial highlights
Full financials- Revenue, FY2026
- $1.14M
- Revenue growth
- -34.6%
- Net income, FY2026
- -$6.21M
- Net margin
- -545.2%
- Cash
- $28.18M
For fiscal 2026 (ended Mar 31, 2026), from SEC filings. Not investment advice.
News · 26 weeks22-50%
2026-05-172026-11-08
Mix1290d
- SEC Filings7(58%)
- Offering3(25%)
- Other2(17%)
Activity · 52 weeks4225 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRChina SXT Pharmaceuticals, Inc. Announces Share ConsolidationTAIZHOU, China, Oct. 22, 2026 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) (the "Company"), today announced that it will effect a share consolidation of its Class A ordinary shares, no par value per share, at a ratio of 1-for-100, effective on October 26, 2026 (the "Share Consolidation"). The Company's Class A ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session on October 26, 2026. Upon the market opening on October 26, 2026, the Company's Class A ordinary shares will continue to be traded on The Nasdaq Stock Market under the symbol "SXTC" with the new CUSIP number G2161P181. Prior to the Share Consolidation, 68,677,5
- SECSEC Form 6-K filed by China SXT Pharmaceuticals Inc.6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- PRChina SXT Pharmaceuticals Inc Announces Termination of Additional Purchase RightTAIZHOU, China, Oct. 21, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ:SXTC) (the "Company"), today announced that it has entered into a termination letter agreement with the purchasers in its registered direct offering announced on October 8, 2026 (the "Offering"). Under the termination letter agreement, the Company and the purchasers have terminated in full the additional purchase right set forth in Section 2.4 of the securities purchase agreement entered into in connection with the Offering. The terminated right had permitted the purchasers, during the 30-day period following the closing of the Offering, to elect to purchase up to an additional $12 million of Class A ordinar
- PRUnivest Securities, LLC Announces Closing of $12 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)New York, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the "Offering") of $12 million for its client China SXT Pharmaceuticals Inc. (NASDAQ:SXTC) (the "Company"), a China-based innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces. Under the terms of the securities purchase agreement, the Company has agreed to sell to certain institutional investors an aggregate of 8,000,000 Class A ordinary shares o
- SECSEC Form 6-K filed by China SXT Pharmaceuticals Inc.6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form 424B5 filed by China SXT Pharmaceuticals Inc.424B5 - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form 6-K filed by China SXT Pharmaceuticals Inc.6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- PRChina SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct OfferingTAIZHOU, China, Oct. 8, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ:SXTC) (the "Company"), today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 8,000,000 Class A ordinary shares of the company, no par value per share (the "Shares") (or pre-funded warrants in lieu thereof), at a purchase price of $1.50 per share in a registered direct offering.The Company also agreed to issue to the same investors 8,000,000 warrants (the "Warrants") with an exercise price of $1.50 per share. The Warrants will be immediately exercisable upon issuance and have a 1-year term from the date of issuance. Eac
- SECSEC Form 6-K filed by China SXT Pharmaceuticals Inc.6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form EFFECT filed by China SXT Pharmaceuticals Inc.EFFECT - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECAmendment: SEC Form F-3/A filed by China SXT Pharmaceuticals Inc.F-3/A - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form 6-K filed by China SXT Pharmaceuticals Inc.6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- PRChina SXT Pharmaceuticals, Inc. Announces Share ConsolidationTAIZHOU, China, Aug. 05, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) (the "Company"), today announced that it will effect a share consolidation of its Class A ordinary shares, no par value per share, and Class B ordinary shares no par value per share, at a ratio of 1-for-80, effective on August 10, 2026 (the "Share Consolidation"). The Company’s Class A ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session on August 10, 2026. Upon the market opening on August 10, 2026, the Company’s Class A ordinary shares will continue to be traded on The Nasdaq Stock Market under the symbol "SXTC" with the new CUSIP number
- PRUnivest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)New York, July 24, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the "Offering") of approximately $9 million for its client China SXT Pharmaceuticals Inc. (NASDAQ:SXTC) (the "Company"), a China-based innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces. Under the terms of the securities purchase agreement, the Company has agreed to sell to certain institutional investors an aggregate of 4,500,000 units (each,
- SECSEC Form 6-K filed by China SXT Pharmaceuticals Inc.6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form 424B5 filed by China SXT Pharmaceuticals Inc.424B5 - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- PRChina SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct OfferingTAIZHOU, China, July 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (NASDAQ:SXTC) (the "Company"), today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of an aggregate of 4,500,000 units (each, a "Unit"), consisting of one Class A ordinary share of the Company, no par value per share (each, a "Class A ordinary share"), and one common warrant (each, a "Warrant"), at a purchase price of $2.00 per Unit in a registered direct offering. Each of the Warrants will have an exercise price of $3.20 per Class A Class A ordinary share, will be immediately exercisable upon issuance, and will expi
- SECSEC Form F-3 filed by China SXT Pharmaceuticals Inc.F-3 - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form 6-K filed by China SXT Pharmaceuticals Inc.6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form 20-F filed by China SXT Pharmaceuticals Inc.20-F - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form 6-K filed by China SXT Pharmaceuticals Inc.6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form 424B5 filed by China SXT Pharmaceuticals Inc.424B5 - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form 6-K filed by China SXT Pharmaceuticals Inc.6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- INSIDERSEC Form 3 filed by new insider Pan Xiaodong Sean3 - China SXT Pharmaceuticals, Inc. (0001723980) (Issuer)
- INSIDERSEC Form 3 filed by new insider Liu Tong Tony3 - China SXT Pharmaceuticals, Inc. (0001723980) (Issuer)
SXTC FAQ
10 questionsWhat does China SXT Pharmaceuticals Inc. do?
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. It offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. The company provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of July 31, 2021, its end-customer base...What is the latest news on SXTC?
In the last 30 days Quantisnow tracked 3 wire items for SXTC: 1 offering, 1 SEC filing and 1 press release or news item. The most recent was published on October 22, 2026.What is SXTC revenue?
China SXT Pharmaceuticals Inc. (SXTC) reported $1.14M of revenue for fiscal 2026 (ended Mar 31, 2026). That is down 34.6% from the year before.Is SXTC profitable?
No. China SXT Pharmaceuticals Inc. reported a net loss of $6.21M for fiscal 2026 (ended Mar 31, 2026).How much cash and debt does SXTC have?
China SXT Pharmaceuticals Inc. reported $28.18M in cash and cash equivalents and $999.6K of debt on its most recent balance sheet in SEC filings.Where does SXTC stock trade?
China SXT Pharmaceuticals Inc. (SXTC) is listed on NASDAQ.What sector and industry is SXTC in?
China SXT Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did China SXT Pharmaceuticals Inc. go public?
China SXT Pharmaceuticals Inc. (SXTC) completed its IPO in 2019.What companies are similar to SXTC?
Notable peers in the same industry include NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.). Compare SXTC side-by-side with any of them on Quantisnow.How can I track SXTC on Quantisnow?
Quantisnow aggregates China SXT Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SXTC to receive live email and push alerts on every new disclosure.